Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Coronary MicrovAscular Diseases Intervention With Compound Danshen Dropping Pills (MAID)

15 de novembro de 2026 atualizado por: Zhang Yun, Qilu Hospital of Shandong University

Coronary MicrovAscular Diseases Intervention With Compound Danshen Dropping Pills(MAID)

Objective: To investigate the effect of Compound Danshen Dripping Pills (CDDP)on improving coronary flow reserve(CFR) in patients with coronary microvascular disease (CMVD) and to evaluate their efficacy and safety.

Study Design: Randomized, double-blind, placebo-controlled, multicenter clinical trial.

Study population: Patients with ischemia-related CMVD and myocardial infarction-related CMVD.

Intervention:Treatment group:standard therapy plus CDDP, Twenty pills (27 mg each) orally, three times daily after meals.Control group:standard therapy plus matching placebo, Twenty pills (27 mg each) orally, three times daily after meals.Treatment duration 12 months.

Primary Endpoint: Change in CFRmax from baseline to Month 12 (ΔCFRmax-12m) by Transthoracic Doppler echocardiography(TTE).

Visão geral do estudo

Descrição detalhada

Rationale for the Study:Coronary Microvascular Disease (CMVD) is a clinical syndrome manifested as effort-induced angina pectoris or laboratory evidence of myocardial ischemia, which results from structural and/or functional abnormalities of the coronary pre-arterioles and arterioles under the effects of multiple pathogenic factors. Impaired coronary microcirculatory function is closely associated with long-term clinical outcomes in patients. A reduced coronary flow reserve (CFR) is not only associated with persistent angina, decreased exercise tolerance, and impaired quality of life, but also independently predicts the risk of cardiovascular death, non-fatal myocardial infarction, heart failure hospitalization, and major adverse cardiovascular events (MACE).Current domestic and international guidelines recommend risk factor control and anti-ischemic therapy as the foundational treatment for CMVD. However, the pathogenesis of CMVD is complex, involving multiple pathological processes such as endothelial dysfunction, microvascular spasm, microvascular remodeling, and inflammation. There is considerable heterogeneity in the treatment benefits among different patients, and evidence-based therapeutic strategies that can definitively improve coronary microcirculatory function and delay disease progression are still lacking.

Basic and clinical studies have demonstrated that the Chinese medicinal compound Compound Danshen Dripping Pills (CDDP) can improve vascular endothelial function and relieve angina pectoris, and it has been widely applied in clinical practice. In the preliminary study entitled Clinical Study on the Effect of Compound Danshen Dripping Pills on Coronary Flow Reserve in Patients with Coronary Microvascular Angina, CDDP effectively improved coronary flow reserve in patients with CMVD. These findings support the value of conducting larger-scale clinical studies to explore its clinical efficacy for CMVD, symptom improvement, and effects measured by the Seattle Angina Questionnaire.

Objective: To investigate the effect of Compound Danshen Dripping Pills (CDDP)on improving coronary flow reserve(CFR) in patients with coronary microvascular disease (CMVD) and to evaluate their efficacy and safety.

Hypothesis: In patients with CMVD receiving standard anti-ischemic therapy, treatment with CDDP for 12 months will significantly improve CFR, reduce major adverse cardiovascular events(MACE), and improve quality of life compared with placebo.

This study adopts a stratified-block randomization design. A total of 496 study participants were divided into two subgroups according to disease diagnosis (Subgroup A: Ischemia-related CMVD; Subgroup B: Myocardial infarction-related CMVD, 248 participants in each subgroup). After the classification of participants into disease-specific subgroups, the system automatically activated the block allocation module corresponding to each subgroup. Participants were assigned to pre-defined groups sequentially according to the real-time enrollment order until the full quota of the subgroup was fulfilled.

During the study, a total of 5 visits will be conducted (Baseline/Screening, Month 3, Month 6, Month 9, and Month 12). At each visit, clinical data will be collected, along with an electrocardiogram (ECG), Canadian Cardiovascular Society (CCS) angina grading, and Seattle Angina Questionnaire (SAQ) scoring. Laboratory tests and echocardiography (including CFR assessment) will be performed at Baseline/Screening, Month 6, and Month 12.

Blood Sampling Protocol: Fasting venous blood samples will be collected at the clinical laboratory of Qilu Hospital of Shandong University on the mornings of the Baseline, Month 6, and Month 12 visits. A total of 3 samples will be collected, with 10 mL drawn each time (total volume: 30 mL). All samples will be sent to the clinical laboratory of Qilu Hospital of Shandong University.

Laboratory Assessments: The blood samples will first be used for routine clinical laboratory tests, including complete blood count (CBC), urinalysis, liver function (ALT, AST), renal function (serum creatinine, urea/BUN), coagulation panel (PT, APTT, TT, FIB), lipid profile (TC, TG, LDL-C, HDL-C), and myocardial enzymes (troponin T [TnT], creatine kinase [CK]). The remaining samples will be utilized for exploratory assessments, such as the detection of inflammatory and endothelial biomarkers, as well as omics screening. Any residual blood samples after the aforementioned tests will be stored uniformly in the cardiovascular laboratory for further exploratory testing in the future.

This study is a large-sample RCT clinical trial targeting CMVD, and is expected to provide evidence-based medical evidence for the treatment of CMVD.

Tipo de estudo

Intervencional

Inscrição (Estimado)

496

Estágio

  • Fase 4

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Shandong
      • Jinan, Shandong, China, 250000
        • Recrutamento
        • Qilu Hospital of Shandong University
        • Contato:
        • Investigador principal:
          • Yun Zhang, MD,PhD

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 80 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Male or female participants aged 18 to 80 years (inclusive).
  2. Within 6 months prior to randomization, coronary CTA, cardiac MRI, or invasive coronary angiography demonstrating coronary stenosis ≤50%; or residual coronary stenosis ≤50% post-revascularization; or coronary stenosis >50% with FFR >0.80.
  3. CFR of the left anterior descending(LAD) artery measured by transthoracic Doppler echocardiography(TTE) <2.5.
  4. Clinical diagnosis of CMVD, meeting any one of the following categories:

(1)Ischemia-related CMVD:

  • Myocardial Ischemia with Non-Obstructive Coronary Arteries: Presence of symptoms consistent with chronic myocardial ischemia, together with objective evidence of reduced CFR and/or coronary microvascular spasm, in the absence of obstructive epicardial coronary artery disease.

    ②Myocardial Ischemia with obstructive Coronary Arteries: Following successful treatment of epicardial coronary artery stenosis with residual luminal stenosis ≤50%, TTE demonstrates persistent impairment of CFR <2.5 in the LAD.

    (2)Myocardial infarction-related CMVD:

  • Myocardial infarction with non-obstructive coronary arteries (MINOCA): coronary stenosis ≤50% by coronary CTA, cardiac MRI, or invasive coronary angiography.

    • Myocardial infarction with obstructive coronary arteries (MIOCA): Typically associated with coronary microvascular obstruction, including but not limited to ST-segment elevation myocardial infarction (STEMI) complicated by coronary microvascular obstruction.

      5.Voluntary provision of written informed consent by the subject or legal representative.

Exclusion Criteria:

  1. Persistent or permanent atrial fibrillation; clinically significant bradyarrhythmias (including severe sinus bradycardia or second-degree type II or higher atrioventricular block); sinus node dysfunction; uncontrolled chronic obstructive pulmonary disease (COPD); or uncontrolled bronchial asthma.
  2. Severe valvular heart disease, cardiomyopathy, LVEF <50%, Takayasu arteritis, or aortic dissection.
  3. Acute myocardial infarction within 1 month prior to randomization.
  4. Unstable angina within 1 week prior to randomization.
  5. Hemorrhagic stroke within the previous 6 months.
  6. Uncontrolled hypertension, defined as systolic blood pressure (SBP) >150 mmHg and/or diastolic blood pressure (DBP) >90 mmHg despite appropriate medical management.
  7. Hepatic dysfunction (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] >2 ×ULN) or renal impairment (estimated glomerular filtration rate [eGFR] ≤60 mL/min/1.73m²).
  8. Pregnant, planning pregnancy, or breastfeeding.
  9. Clinically significant respiratory, gastrointestinal, hematologic, infectious, immunologic, endocrine, neurological, psychiatric, or malignant diseases that, in the investigator's judgment, may pose an unacceptable risk to the participant or interfere with study participation.
  10. Current requirement for anticoagulation therapy with warfarin; current use of nicorandil; or concomitant treatment with other traditional Chinese medicine (TCM) preparations.
  11. Active bleeding or clinically significant bleeding tendency, including platelet count <50×10⁹/L or documented coagulation disorders.
  12. Known or suspected hypersensitivity to intra-arterial contrast media, blood or blood products, or the investigational medicinal product.
  13. Participation in another interventional clinical trial within 3 months prior to randomization or concurrent participation in another clinical study.
  14. Any other medical condition or circumstance that, in the opinion of the investigator, would make the participant unsuitable for enrollment in this study.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Conventional treatment + Compound Danshen Dripping Pills 540 mg

Participants receive conventional treatment plus Compound Danshen Dripping Pills (CDDP), 20 pills (540 mg) orally three times daily for 12 months.

20 pills (540 mg) orally three times daily for 12 months. Each pill weighs 27 mg, containing Radix Salviae miltiorrhizae, Radix Notoginseng, and Borneolum Syntheticum. Manufactured and supplied by Tasly Pharmaceutical Group Co., Ltd.

Outros nomes:
  • CDDP
  • Fufang Danshen Diwan
  • Cardiotonic Pill
  • Dantonic Pill
  • T89
Comparador de Placebo: Conventional treatment + matching placebo

Participants receive conventional treatment plus placebo pills matching CDDP in appearance, 20 pills orally three times daily for 12 months.

Placebo pills identical to Compound Danshen Dripping Pills in appearance, taste, and packaging, 20 pills orally three times daily for 12 months.

Outros nomes:
  • Placebo correspondente

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change from baseline in peak coronary flow reserve (CFRmax) of the left anterior descending artery
Prazo: Baseline, 6 months, and 12 months

CFRmax is defined as the ratio of hyperemic to basal peak diastolic flow velocity (PDV) in the mid-to-distal left anterior descending artery, measured by transthoracic Doppler echocardiography (TTDE) during regadenoson-induced maximal hyperemia (regadenoson 0.4 mg/5 mL administered as a single intravenous bolus over approximately 10 seconds, followed by a saline flush). Measurements are performed at baseline, 6 months, and 12 months. Change from baseline at each time point is calculated as the value at that time point minus the baseline value. The primary analysis time point is 12 months.

Baseline, 6 months, and 12 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change from baseline in mean coronary flow reserve (CFRmean) of the left anterior descending artery
Prazo: Baseline, 6 months, and 12 months

CFRmean is defined as the ratio of hyperemic to basal mean diastolic flow velocity (MDV) in the mid-to-distal left anterior descending artery, measured by transthoracic Doppler echocardiography (TTDE) during regadenoson-induced maximal hyperemia (regadenoson 0.4 mg/5 mL administered as a single intravenous bolus over approximately 10 seconds, followed by a saline flush). Measurements are performed at baseline, 6 months, and 12 months. Change from baseline at each time point is calculated as the value at that time point minus the baseline value.

Baseline, 6 months, and 12 months
Change from baseline in Seattle Angina Questionnaire (SAQ) score
Prazo: Baseline, 3, 6, 9, and 12 months

The Seattle Angina Questionnaire (SAQ) is a disease-specific health status measure for coronary artery disease. Each of its five domains (Physical Limitation, Anginal Stability, Anginal Frequency, Treatment Satisfaction, and Disease Perception/Quality of Life) is scored from 0 to 100, with higher scores indicating better health status (fewer symptoms/limitations). Change from baseline is calculated as the score at each time point minus the baseline score.

Baseline, 3, 6, 9, and 12 months
Change from baseline in CCS angina class
Prazo: Baseline, 3, 6, 9, and 12 months

Angina severity is classified by the Canadian Cardiovascular Society (CCS) angina classification, ranging from Class I (angina only during strenuous exertion; least severe) to Class IV (angina at rest; most severe), where a higher class indicates a worse outcome. Improvement is defined as a reduction of ≥1 CCS class grade from baseline at each assessment time point.

Baseline, 3, 6, 9, and 12 months
Incidence of major adverse cardiovascular events (MACE) within 12 months
Prazo: From randomization/enrollment through 12 months

MACE is a composite endpoint defined as the occurrence of any of the following components during the 12-month follow-up period: (1) cardiovascular death; (2) non-fatal myocardial infarction; (3) revascularization; (4) hospitalization for angina pectoris; and (5) hospitalization for heart failure.

From randomization/enrollment through 12 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Yun Zhang, MD,PhD, Department of Cardiology,Qilu Hospital of Shandong University

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de novembro de 2026

Conclusão Primária (Estimado)

1 de novembro de 2028

Conclusão do estudo (Estimado)

1 de dezembro de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

12 de outubro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

20 de outubro de 2026

Primeira postagem (Real)

21 de outubro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

18 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

15 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

Individual participant data will not be shared. The informed consent form approved by the ethics committee and signed by participants did not include provisions for sharing de-identified individual participant data beyond the research team or with external investigators, and additional consent for data sharing was not obtained at the time of enrollment.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever